Platform Immune Monitoring
The Platform Immune Monitoring (PIM) provides an extensive set of technologies to study immunological parameters in patients with immune-mediated diseases and to assess the effects of immune modulatory treatment. Standardised application of diagnostic and state-of-the-art research methodologies enable validated biomarker research and comparison of biomarker profiles between patient cohorts. Upon request we develop, optimise and validate novel analytical tests to facilitate research on disease-specific parameters.
- High throughput and sensitive measurement of proteins (cytokines, chemokines, and growth factors) in many biological fluids using multiplex immunoassays (Luminex; 160+ analytes in < 250 μl or Olink technology (~1200 proteins in < 20 μl);
- Extensive phenotyping of leukocytes (e.g. T, B and NK(T) cell lymphocyte subsets) using flow cytometry;
- Functional assays and assessment of intracellular cytokine profiles in (un)stimulated lymphocytes;
- Assessment of allergenicity of proteins and patient allergic phenotypes by cellular testing in the Basophil Activation Test (BAT).
The Platform Immune Monitoring is GCP compliant and is ISO9001:2019 accredited. Our services can be used to support regulatory dossiers.